300942 易瑞生物
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)-0.184-20.3888.68931.66512.150
总资产报酬率 ROA (%)-0.113-14.0156.81426.20010.286
投入资产回报率 ROIC (%)-0.124-15.4777.65929.59011.415

边际利润分析
销售毛利率 (%)68.63749.92956.50671.63275.366
营业利润率 (%)-1.104-68.98714.28344.89729.059
息税前利润/营业总收入 (%)0.465-71.06912.57745.69332.821
净利润/营业总收入 (%)-1.884-72.79812.03439.57425.323

收益指标分析
经营活动净收益/利润总额(%)-83.12144.059138.51192.30095.754
价值变动净收益/利润总额(%)216.91130.4192.8203.60611.924
营业外收支净额/利润总额(%)7.5851.404-3.395-0.089-1.571

偿债能力分析
流动比率 (X)4.8925.3873.3765.7316.735
速动比率 (X)4.6335.1582.8725.1325.947
资产负债率 (%)39.11637.42524.77717.86915.914
带息债务/全部投入资本 (%)32.12829.32710.9621.914--
股东权益/带息债务 (%)206.715234.117763.4644,870.8585,359.819
股东权益/负债合计 (%)155.407167.253303.659458.756528.428
利息保障倍数 (X)0.28064.635-10.16754.6957.794

营运能力分析
应收账款周转天数 (天)133.475113.35747.41248.0020.000
存货周转天数 (天)200.739186.842117.164165.0690.000